Gotowa bibliografia na temat „Heparin”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Heparin”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Heparin"
Zvibel, I., E. Halay i L. M. Reid. "Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors". Molecular and Cellular Biology 11, nr 1 (styczeń 1991): 108–16. http://dx.doi.org/10.1128/mcb.11.1.108-116.1991.
Pełny tekst źródłaZvibel, I., E. Halay i L. M. Reid. "Heparin and hormonal regulation of mRNA synthesis and abundance of autocrine growth factors: relevance to clonal growth of tumors." Molecular and Cellular Biology 11, nr 1 (styczeń 1991): 108–16. http://dx.doi.org/10.1128/mcb.11.1.108.
Pełny tekst źródłaBar-Ner, M., A. Eldor, L. Wasserman, Y. Matzner, IR Cohen, Z. Fuks i I. Vlodavsky. "Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species". Blood 70, nr 2 (1.08.1987): 551–57. http://dx.doi.org/10.1182/blood.v70.2.551.551.
Pełny tekst źródłaBar-Ner, M., A. Eldor, L. Wasserman, Y. Matzner, IR Cohen, Z. Fuks i I. Vlodavsky. "Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species". Blood 70, nr 2 (1.08.1987): 551–57. http://dx.doi.org/10.1182/blood.v70.2.551.bloodjournal702551.
Pełny tekst źródłaFareed, Jawed, Adrian Sonevytsky, Omer Iqbal, Walter P. Jeske, Massimo Iacobelli i Debra Hoppensteadt. "Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications." Blood 108, nr 11 (16.11.2006): 1626. http://dx.doi.org/10.1182/blood.v108.11.1626.1626.
Pełny tekst źródłaPinhal, Maria A. S., Isabel A. N. Santos, Irani F. Silva, Carl P. Dietrich i Helena B. Nader. "Minimum Fragments of the Heparin Molecule Able to Produce the Accumulation and Change of the Sulfation Pattern of an Antithrombotic Heparan Sulfate from Endothelial Cells". Thrombosis and Haemostasis 74, nr 04 (1995): 1169–74. http://dx.doi.org/10.1055/s-0038-1649898.
Pełny tekst źródłaHovingh, P., M. Piepkorn i A. Linker. "Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates". Biochemical Journal 237, nr 2 (15.07.1986): 573–81. http://dx.doi.org/10.1042/bj2370573.
Pełny tekst źródłaSieme, Daniel, Christian Griesinger i Nasrollah Rezaei-Ghaleh. "Metal Binding to Sodium Heparin Monitored by Quadrupolar NMR". International Journal of Molecular Sciences 23, nr 21 (29.10.2022): 13185. http://dx.doi.org/10.3390/ijms232113185.
Pełny tekst źródłaDiamond, M. S., R. Alon, C. A. Parkos, M. T. Quinn i T. A. Springer. "Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1)." Journal of Cell Biology 130, nr 6 (15.09.1995): 1473–82. http://dx.doi.org/10.1083/jcb.130.6.1473.
Pełny tekst źródłaBasic-Micic, M., K. Krupinski, A. Thalhammer, C. Dechent, Ch Rauschenbach i H. K. Breddin. "Beeinflußt niedermolekulares Heparin die Thrombozytenfunktion?" Hämostaseologie 09, nr 05 (wrzesień 1989): 248–57. http://dx.doi.org/10.1055/s-0038-1655278.
Pełny tekst źródłaRozprawy doktorskie na temat "Heparin"
Raghuraman, Arjun. "Designing Non-saccharide Heparin/Heparan Sulfate Mimics". Online version available 8/19/2013, 2008. http://hdl.handle.net/10156/2269.
Pełny tekst źródłaCarelli, Guareide [UNESP]. "Associação de doses baixas de heparina não fracionada e de heparina de baixo peso molecular na prevenção de trombose venosa experimental". Universidade Estadual Paulista (UNESP), 2003. http://hdl.handle.net/11449/88962.
Pełny tekst źródłaA heparina é um glicosaminoglicano sulfatado, de cadeia longa, que vem sendo largamente utilizada, desde meados do século passado, no tratamento e profilaxia das tromboses arteriais e venosas e cuja utilização permitiu o desenvolvimento das cirurgias cardíaca e vascular. As heparinas de baixo peso molecular (HBPM) são frações ou fragmentos da heparina separados do complexo polissacarídico por extração com solvente ou por gel filtração, ou por clivagem química ou enzimática aplicada antes dessa separação física. No presente artigo são revistos os diversos aspectos da estrutura, mecanismo de ação, farmacocinética, monitorização laboratorial e aplicações clínicas de ambos os tipos de substâncias, sendo chamada a atenção para as diferenças entre elas. As HBPM tendem a substituir a heparina não fracionada, na maior parte de suas indicações, por serem de mais simples utilização e apresentarem maior eficácia e segurança em algumas indicações, embora sejam de custo mais alto.
Heparin is a long sulfated glucosaminoglicane chain has been used in the treatment and prophylaxis of arterial and venous thombosis since the 50’s of last century. Its use also aided the development of cardiac and vascular surgery. Low molecular weight heparins (LMWH) are fractions or fragments of heparin separated from the polysaccharide complex by solvent extraction or gel filtration, or by chemical or enzymatic cleavage, before the extraction. In this article the main aspects of structure, mechanism of action, pharmacokinetics, laboratorial control, and clinical indications of both kinds of substances are reviewed and their main differences emphasized. Despite their high cost, LMWH presently tend to substitute unfractionated heparin in the majority of indications because of its simpler use, high efficacy and security in some cases.
Noti, Christian. "Synthesis of heparin oligosaccharides and the creation of heparin microarrays /". Zürich : ETH, 2007. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=17150.
Pełny tekst źródłaAlbig, Thomas. "Synthese und Untersuchung von Heparin-Prodrugs auf Glyceridbasis /". [S.l.] : [s.n.], 1986. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=7990.
Pełny tekst źródłaJaime, Rodríguez Juan Carlos. "Unveiling Heparin and Heparan Sulfate Conformations : a Journey into Paramagnetic NMR Analysis". Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASF016.
Pełny tekst źródłaHeparin (HP) and heparan sulfates (HS) are linear and sulfated polysaccharides that play various biological roles, including cell growth, adhesion, viral recognition, and cancer metastasis. Their molecular diversity and sulfation pattern contribute to their biological versatility. Furthermore, their conformational flexibility has been studied through methods such as X-ray crystallography and NMR. Despite advancements, interpreting these features remains challenging, especially for long saccharides. This thesis proposes the use of paramagnetic NMR, particularly pseudo-contact shifts (PCS) measurements, in studying the conformation of HS molecules. Results obtained on an HS octasaccharide show a correlation between experimental PCS and molecular dynamics simulations, suggesting specific conformations of IdoA motifs. These findings expand the applications of paramagnetic NMR, paving the way for a thorough analysis of protein-polysaccharide interactions
Nazir, Ahmad Mohamad Farha. "The role of heparin and heparin-binding growth factors in pre-eclampsia". Thesis, Middlesex University, 2016. http://eprints.mdx.ac.uk/21321/.
Pełny tekst źródłaKRISHNASAMY, CHANDRAVEL. "MOLECULAR MODELING STUDIES OF HEPARIN AND HEPARIN MIMETICS BINDING TO COAGULATION PROTEINS". VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/18.
Pełny tekst źródłaSachchidanand. "Heparin binding to fibronectin". Thesis, University of Oxford, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.393457.
Pełny tekst źródłaEvans, Dyfed Ll. "The heparin activateable serpins". Thesis, University of Cambridge, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.385390.
Pełny tekst źródłaFreitas, Cristiane Fonseca. "Efeitos do Bay 41-2272 na hipertensão pulmonar experimental em cães anestesiados". [s.n.], 2007. http://repositorio.unicamp.br/jspui/handle/REPOSIP/308951.
Pełny tekst źródłaTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-09T08:05:23Z (GMT). No. of bitstreams: 1 Freitas_CristianeFonseca_D.pdf: 2119434 bytes, checksum: 58a318beb1d3946d852e010325a6187c (MD5) Previous issue date: 2007
Resumo: Neste estudo, investigamos os efeitos protetores do BAY 41-2272 sobre a hipertensao pulmonar induzida pelo complexo heparina-protamina e hipoxia em cães anestesiados. Os animais foram anestesiados com pentobarbital sodico (Hypnol, 30mg/kg, iv) combinado com citrato de fentanila (0,01 mg/kg/h, i.v.) e diazepam (0,25mg/kg/h, iv). A hipertensao pulmonar pelo complexo heparina-protamina foi induzida com a administracao de 500 UI/kg de heparina, seguida da administracao de protamina (10 mg/kg). A interacao heparina-protamina causou aumento de aproximadamente 350% da pressao media da arteria pulmonar (PMAP), acompanhado de aumento significativo do indice de resistencia vascular pulmonar (IRVP) e da pressao capilar pulmonar (PcP). Este aumento foi significativo 2 min apos a injecao de protamina, mantendo-se significativamente elevado ate aproximadamente 5 minutos apos administracao da mesma. Ao mesmo tempo em que se detectou a hipertensao pulmonar, observamos reducao significativa da pressao arterial media (PAM). Observamos ainda um aumento significativo da frequencia cardiaca (FC) aos 2 minutos apos administracao da protamina com discreta diminuicao do indice cardiaco (IC). O indice de resistencia vascular sistemica (IRVS) nao sofreu alteracoes significativas. A saturacao do oxigenio (SpO2) foi significativamente diminuida apos a formacao do complexo heparina-protamina. Nos animais tratados com BAY 41-2272 (10 /kg/min, i.v.), observamos reducao marcante do aumento da PMAP, do IRVP e da PcP. Por outro lado, este tratamento potencializou a reducao da PAM. Alem disso, o BAY 41-2272 reduziu significantemente o IRVS e aumentou a FC. A diminuicao da SpO2 foi atenuada significativamente pelo BAY 41- 2272. Os niveis plasmaticos de GMPc foram dosados aos 2 min apos a formacao do complexo heparina-protamina, tendo-se mostrado elevados no grupo tratado com o BAY41-2272. O tempo de tromboplastina parcial ativado (TTPA) nao apresentou alteração significativa no tratamento com o BAY 41-2272. O veiculo do BAY 41-2272 (DMSO 30%) nao alterou significativamente os parametros estudados. A hipertensao pulmonar por hipoxia foi induzida com a instalacao de uma baixa tensao de oxigenio (FiO2=12%). Nesta circunstancia, a PMAP elevou-se em aproximadamente 280% aos 5 minutos, mantendo-se significativamente elevada ate 15 minutos apos instalacao da hipoxia. A elevacao da PMAP foi acompanhada de aumentos significativos no IRVP e PcP. A PAM, IRVS, FC e IC nao apresentaram alterações significativas. A SpO2 diminuiu na presenca da hipoxia. O tratamento com BAY 41-2272 (10 /kg/min, i.v.), reduziu significativamente a PMAP, PcP e IRVP. O IRVS foi significativamente potencializado pelo BAY 41-2272. A PAM, FC e IC nao alteraram significativamente. A diminuicao da SpO2 foi atenuada significativamente pelo BAY 41- 2272. Os niveis plasmaticos de GMPc elevaram-se significativamente no grupo tratado com o BAY 41-2272. Em conclusao, o BAY 41-2272 atenuou a acao vasoconstritora pulmonar induzida pelo complexo heparina-protamina e hipoxia levando a uma prevencao da hipertensao pulmonar.
Doutorado
Farmacologia
Doutor em Farmacologia
Książki na temat "Heparin"
1960-, Warkentin Theodore E., i Greinacher Andreas, red. Heparin-induced thrombocytopenia. Wyd. 4. New York: Informa Healthcare USA, 2007.
Znajdź pełny tekst źródła1960-, Warkentin Theodore E., i Greinacher Andreas, red. Heparin-induced thrombocytopenia. Wyd. 3. New York: Marcel Dekker, 2004.
Znajdź pełny tekst źródłaWarkentin, Theodore E., i Andreas Greinacher. Heparin-induced thrombocytopenia. Wyd. 4. New York: Informa Healthcare, 2007.
Znajdź pełny tekst źródła1960-, Warkentin Theodore E., i Greinacher Andreas, red. Heparin-induced thrombocytopenia. New York: Dekker, 2000.
Znajdź pełny tekst źródła1960-, Warkentin Theodore E., i Greinacher Andreas, red. Heparin-induced thrombocytopenia. Wyd. 2. New York: Dekker, 2001.
Znajdź pełny tekst źródłaLane, David A., Ingemar Björk i Ulf Lindahl, red. Heparin and Related Polysaccharides. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4899-2444-5.
Pełny tekst źródła1949-, Lane D. A., Björk Ingemar i Lindahl Ulf 1939-, red. Heparin and related polysaccharides. New York: Plenum Press, 1992.
Znajdź pełny tekst źródłaBarrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.
Znajdź pełny tekst źródłaChang, Shau-Feng. Studies on structure, heparin-binding, and gene expression of hepatic lipase. München: Dissertationsverlag NG Kopierladen, 1993.
Znajdź pełny tekst źródłainstitutet, Karolinska, red. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity: Effects of heparin and a low molecular weight heparin fragment (Fragmin®). Stockholm: Acta medica Scandinavica, 1988.
Znajdź pełny tekst źródłaCzęści książek na temat "Heparin"
Harr, Jeffrey N., Philip F. Stahel, Phillip D. Levy, Antoine Vieillard-Baron, Yang Xue, Muhammad N. Iqbal, Jeffrey Chan i in. "Heparin". W Encyclopedia of Intensive Care Medicine, 1071–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_715.
Pełny tekst źródłaRoth, Elliot J. "Heparin". W Encyclopedia of Clinical Neuropsychology, 1686–87. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_2219.
Pełny tekst źródłaPetroianu, Georg, i Peter Michael Osswald. "Heparin". W Anästhesie in Frage und Antwort, 79–81. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-05715-5_28.
Pełny tekst źródłaPetroianu, Georg, i Peter Michael Osswald. "Heparin". W Anästhesie in Frage und Antwort, 99–101. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-662-05717-9_43.
Pełny tekst źródłaRoth, Elliot J. "Heparin". W Encyclopedia of Clinical Neuropsychology, 1–2. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-56782-2_2219-2.
Pełny tekst źródłaWilson, John Fawcett. "Heparin". W The Immunoassay Kit Directory, 1555. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0679-5_26.
Pełny tekst źródłaWatkins, Evan, i Daniel Thomas Ginat. "Heparin". W Neuroimaging Pharmacopoeia, 257–60. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-12715-6_33.
Pełny tekst źródłaWatkins, Evan, Daniel Thomas Ginat i Juan E. Small. "Heparin". W Neuroimaging Pharmacopoeia, 313–16. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08774-5_44.
Pełny tekst źródłaBährle-Rapp, Marina. "Heparin". W Springer Lexikon Kosmetik und Körperpflege, 254. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-71095-0_4679.
Pełny tekst źródłaRoth, Elliot J. "Heparin". W Encyclopedia of Clinical Neuropsychology, 1236–37. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_2219.
Pełny tekst źródłaStreszczenia konferencji na temat "Heparin"
Eldor, A., M. Bar-Ner, L. Wasserman, Y. matzner, Z. Fuks i I. Viodavsky. "HEPARIN AND NON-ANTICOAGULANT HEPARINS INHIBIT HEPARANASE ACTIVITY IN NORMAL AND MALIGNANT CELLS:POSSIBLE THERAPEUTIC USE IN PREVENTION OF EXTRAVASATION AND DISSEMINATION OF BLOOD BORNE CELLS". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643664.
Pełny tekst źródłaBorowska, A., D. Lauri, A. Maggi, E. Dejana, G. de Gaetano i J. Pangrazzi. "IMPAIREMENT OF PRIMARY HAEMOSTASIS BY LMW-HEPARINS". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643172.
Pełny tekst źródłaMaggi, A., T. W. Barrowcliffe, E. Gray, M. B. Donati, R. E. Merton i I. Pangrazzi. "RELATIONSHIP BETWEEN HAEMORRHAGIC AND LIPASE-RET EASING PROPERTIES OF HEPARIN AND LMV HEPARIN". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642929.
Pełny tekst źródłaDawes, J., i D. S. Pepper. "A COMPARISON OF THE BINDING OF ANTITHROMBIN III AND HEPARIN COFACTOR II TO HEPARINS, NATURALLY OCCURRING GLYCOSAMINOGLYCANS AND OTHER SULPHATED POLYMERS". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642827.
Pełny tekst źródłaMessmore, H., B. Griffin, J. Seghatchian i E. Coyne. "HIGH CONCENTRATIONS OF HEPARIN ARE MORE INHIBITORY TO PLATE- AGGREGATION IN-VITRO THAN ARE LOW MOLECULAR WEIGHT HEPARINS AND HEPARINOIDS AT THE SAME CONCENTRATION". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644186.
Pełny tekst źródłaOrdu, Y., J. Augustin, E. V. Hodenberg, V. Bode i J. Harenberg. "COMPARATIVE CLINICAL PHARMACOLOGY OF LOW MOLECULAR WEIGHT HEPARINS IN MAN". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643228.
Pełny tekst źródłaJackson, Craig M. "A DEFINITION OF HEPARIN ANTICOAGULANT POTENCY APPLICABLE TO ALL HEPARINS AND HEPARIN-LIKE SUBSTANCES AND ITS PRACTICAL APPLICATION IN ASSAYING HEPARIN". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642928.
Pełny tekst źródłaZimmerman, R. A., C. T. Rieger, K. Hübner, C. W. Harenber i W. Kübler. "EXPERIMENTAL THROMBUS FORMATION AND HAEMOSTASIS OF DIFFERENT LOW MOLECULAR WEIGHT HEPARINS AND DOSAGES". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644162.
Pełny tekst źródłaRathjen, A., i Carolyn L. Geczy. "PRODUCTION AND CHARACTERISATION OF MONOCLONAL ANTIBODIES AGAINST HEPARIN Deborah". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644188.
Pełny tekst źródłaFenichel, R. L., W. Carmint, B. Small i J. Willis. "COMPARISON OF THE ANTITHROMBOTIC, ANTICLOTTING AND ANTIPLATELET AGGREGATORY ACTIVITIES OFLOW MOLECULAR WEIGHT RD HEPARIN WITH HEPARIN". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644854.
Pełny tekst źródłaRaporty organizacyjne na temat "Heparin"
Carlin, Stephanie, Andrew M. Morris, Zainab B. Abdurrahman, Jacob J. Bailey, Martin E. Betts, William Ciccotelli, Bradley J. Langford i in. Heparin Anticoagulation for Hospitalized Patients with COVID-19. Ontario COVID-19 Science Advisory Table, wrzesień 2021. http://dx.doi.org/10.47326/ocsat.2021.02.41.1.0.
Pełny tekst źródłaUpchurch, G. R., Valeri Jr., Khuri C. R., Rohrer S. F., Welch M. J. i G. N. The Effect of Heparin on Fibrinolytic Activity and Platelet Function. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1995. http://dx.doi.org/10.21236/ada360274.
Pełny tekst źródłaSalomon, David. The Role of Heparin-Binding EGF-Like Growth Factor in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, październik 1995. http://dx.doi.org/10.21236/ada300394.
Pełny tekst źródłaKhuri, S. F., C. R. Valeri, J. Loscalzo, M. Weinstein i V. Birjiniuk. Heparin Causes Platelet Dysfunction and Induces Fibrinolysis Before the Institution of Cardiopulmonary Bypass. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 1995. http://dx.doi.org/10.21236/ada360259.
Pełny tekst źródłaChen, Chen, Peng Chen, Xia Liu i Hua Li. Combined 5-Fluorouracil and Low Molecular Weight Heparin for the Prevention of Postoperative Proliferative Vitreoretinopathy in Patients with Retinal Detachment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, sierpień 2021. http://dx.doi.org/10.37766/inplasy2021.8.0117.
Pełny tekst źródłaLi, Rui, Xiang Gao, Tao Zhou, Yunjie Li, Jianhui Wang i Peirong Zhang. Regional citrate versus heparin anticoagulation for CRRT in critically ill patients: a meta-analysis of RCTS. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, grudzień 2021. http://dx.doi.org/10.37766/inplasy2021.12.0093.
Pełny tekst źródłaChan, Shan-Ho, Cheng-Kai Huang, Po-Nien Hou i Jay Wu. Meta-Analysis of the Effectiveness of Heparin in Suppressing Physiological Myocardial FDG Uptake in PET/CT. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, marzec 2023. http://dx.doi.org/10.37766/inplasy2023.3.0015.
Pełny tekst źródłaWei, Qingqing, Weiying Wang, Guobin Miao, Li Li, Ge Wang, Chang Meng i Peng Liu. Aspirin Versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis in Patients after Postoperative Joint Surgery: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2023. http://dx.doi.org/10.37766/inplasy2023.2.0117.
Pełny tekst źródłaLin, Yun-Kuan, Yu-Ning Huang i Jen-Hung Wang. Effects of heparin on venom-induced consumption coagulopathy: protocol for a systematic review, meta-analysis, and trial sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2024. http://dx.doi.org/10.37766/inplasy2024.2.0070.
Pełny tekst źródłahuang, kun, yan sun i hai jiang. Effect of low molecular weight heparin combined with aspirin on pregnancy outcomes of unexplained recurrent abortion: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, październik 2023. http://dx.doi.org/10.37766/inplasy2023.10.0005.
Pełny tekst źródła